Article Text

Download PDFPDF

LP-139 Baseline characteristics of a longitudinal, multinational, multiethnic study of lupus patients, with or without lupus nephritis
  1. Romina Nieto1,
  2. Rosana Quintana1,
  3. Eduardo F Borba1,
  4. Lucia Hernández1,
  5. Diana Fernández-Ávila1,
  6. Laura Maurelli1,
  7. Paula Alba1,
  8. Florencia Bordón1,
  9. Fernando Arizpe1,
  10. Guillermo Berbotto1,
  11. Rosa Serrano-Morales1,
  12. María Constanza Bertolaccini1,
  13. Eduardo Kerzberg1,
  14. María de los Ángeles Gargiulo1,
  15. Anabella Rodríguez1,
  16. Vitalina Sousa Barbosa1,
  17. Fernando Cavalcanti1,
  18. Laissa Cristina Alves Alvino1,
  19. Luciana Parente Costa Seguro1,
  20. Lucas Victoria De Oliveira Martins1,
  21. Oscar Neira1,
  22. Loreto Massardo1,
  23. Gustavo Aroca Martínez1,
  24. Ivana Nieto Aristizábal1,
  25. A Paul1,
  26. Antonio Iglesias Gamarra1,
  27. Andrés Zuñiga Vera1,
  28. Olga Vera lastra1,
  29. Mario Pérez cristóbal1,
  30. Eduardo Martín-Nares1,
  31. Luis Amezcua-guerra1,
  32. Yelitza González-Bello1,
  33. José Octavio González Enriquez1,
  34. Dionicio Galarza-Delgado1,
  35. Carolina Vázquez Vázquez1,
  36. Marcelo Barrios1,
  37. Magaly Alba Linares1,
  38. Cristina Reategui1,
  39. Ana Mabel Quirós-alva1,
  40. Teresandris Polanco1,
  41. Carina Pizzarossa1,
  42. Martín Rebella1,
  43. María Elena Crespo1,
  44. Álvaro Danza1,
  45. Eloisa Bonfa1,
  46. Graciela S Alarcón1,
  47. Federico Zazzetti2,
  48. Ashley Orillion3,
  49. Urbano Sbarigia4 and
  50. Guillermo J Pons-Estel1
  1. 1Rheumatology, GLADEL (Latin American Group for the Study of Lupus), Argentina
  2. 2Rheumatology, Janssen Pharmaceutical Companies of Johnson and Johnson, Horsham, PA, USA
  3. 3Rheumatology, Janssen Pharmaceutical Companies of Johnson and Johnson, Spring House, PA, USA
  4. 4Rheumatology, Janssen Pharmaceutica NV, Beerse, Belgium


Background Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological and treatment characteristics of a multicenter and multiethnic Latin American SLE cohort of patients with or without lupus nephritis (LN).

Methods GLADEL 2.0 is an ongoing observational cohort. Patients were categorized according to renal involvement: Group I (LN never); Group II (prevalent renal involvement currently inactive); Group III (prevalent renal involvement, currently active) and Group IV (incident renal involvement). Demographic, clinical manifestations, treatments, disease activity were examined at baseline. A descriptive cross-sectional analysis was performed.

Results A total of 991 SLE patients were included, 884 (89.2%) female and 656 (68.3%) Mestizos (Amerindian and European ancestry). Median (IQR) age at cohort entry was 35 (28–45) years and disease duration were 67 months (18–139). Patients with incident LN had a higher proportion of males, were younger, had shorter disease duration and were more frequently Mestizos. Pericarditis and anti-dsDNA were less frequent in group I and MMF in groups I and IV (table 1). A predominance of class IV (49%) was evidenced in 510 patients in which a kidney biopsy was performed (349 prevalent LN and 161 incident LN).

Conclusions Baseline characteristics of GLADEL 2.0 well characterized lupus patients’ cohort with or without LN are described with distinct demographic, clinical and laboratory patterns that will allow both centralized laboratory evaluation of urinary biomarkers and exploratory biomarker analyses including transcriptome and their impact on the outcome of these patients.

Abstract LP-139 Table 1

Sociodemographic and clinical characteristics and treatment at cohort entry

  • Systemic lupus erythematosus
  • Registries
  • Autoantibodies

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.